Evidence map›Paper›PMID 34018704›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021

Control of Brain State Transitions with a Photoswitchable Muscarinic Agonist.

Almudena Barbero-Castillo, Fabio Riefolo, Carlo Matera, Sara Caldas-Martínez, Pedro Mateos-Aparicio, Julia F Weinert, Aida Garrido-Charles, Enrique Claro, Maria V Sanchez-Vives, Pau Gorostiza

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Real-Time Optical Control of CB1 Receptor SignalingJournal of the American Chemical Society · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Control of Brain State Transitions with a Photoswitchable Muscarinic Agonist.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Almudena Barbero-CastilloInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 08036, Spain.ORCID 0000-0003-0056-2348
Fabio RiefoloInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology, Barcelona, 08028, Spain.ORCID 0000-0002-6762-2619
Carlo MateraInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology, Barcelona, 08028, Spain.ORCID 0000-0001-6939-3859
Sara Caldas-MartínezInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 08036, Spain.ORCID 0000-0003-2527-2056
Pedro Mateos-AparicioInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 08036, Spain.ORCID 0000-0001-8513-4005
Julia F WeinertInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 08036, Spain.ORCID 0000-0003-4413-7212
Aida Garrido-CharlesInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology, Barcelona, 08028, Spain.
Enrique ClaroInstitut de Neurociències and Departament de Bioquímica i Biologia Molecular, Unitat de Bioquímica de Medicina, Universitat Autònoma de Barcelona (UAB), Barcelona, 08193, Spain.ORCID 0000-0002-7592-7906
Maria V Sanchez-VivesInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 08036, Spain.ORCID 0000-0002-8437-9083
Pau GorostizaInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology, Barcelona, 08028, Spain.ORCID 0000-0002-7268-5577
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESInstitució Catalana de Recerca i Estudis Avançats · ESUniversitat Autònoma de Barcelona · ESUniversity of Milan · IT

Funding

Agency for Management of University and Research Grants/Generalitat de Catalunya 2017-SGR-1442Commission for Universities and Research of the Department of InnovationEuropean Research ERA-Net SynBio programmeEuropean Union Regional Development FundEuropean Union Research and Innovation Programme Horizon 2020 101016787 (DEEPER)European Union Research and Innovation Programme Horizon 2020 Specific Grant Agreement No. 785907 (Human Brain Project SGA2)European Union Research and Innovation Programme Horizon 2020 Specific Grant Agreement No. 945539 (Human Brain Project SGA3)Fundaluce foundationMinistry of Economy and Competitiveness CTQ2016- 80066-RSpanish Ministry of Science and Innovation BFU2017-85048-RUniversities, and Enterprise of the Generalitat de Catalunya IU16-011508
6 · The paper itself

Abstract

The ability to control neural activity is essential for research not only in basic neuroscience, as spatiotemporal control of activity is a fundamental experimental tool, but also in clinical neurology for therapeutic brain interventions. Transcranial-magnetic, ultrasound, and alternating/direct current (AC/DC) stimulation are some available means of spatiotemporal controlled neuromodulation. There is also light-mediated control, such as optogenetics, which has revolutionized neuroscience research, yet its clinical translation is hampered by the need for gene manipulation. As a drug-based light-mediated control, the effect of a photoswitchable muscarinic agonist (Phthalimide-Azo-Iper (PAI)) on a brain network is evaluated in this study. First, the conditions to manipulate M2 muscarinic receptors with light in the experimental setup are determined. Next, physiological synchronous emergent cortical activity consisting of slow oscillations-as in slow wave sleep-is transformed into a higher frequency pattern in the cerebral cortex, both in vitro and in vivo, as a consequence of PAI activation with light. These results open the way to study cholinergic neuromodulation and to control spatiotemporal patterns of activity in different brain states, their transitions, and their links to cognition and behavior. The approach can be applied to different organisms and does not require genetic manipulation, which would make it translational to humans.

Indexed as

AnimalsBrainFerretsMiceMice, Inbred C57BLModels, AnimalMuscarinic AgonistsMuscarinic Agonistsbrain stateslight-mediated controlmuscarinic acetylcholine receptorsneuromodulationphotopharmacology

Identifiers

PMID34018704
PMCPMC8292914
OpenAlexW3161268097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.